Denosumab
Amgen
['denosumab']
 presents f/u of abcsg-18: placebo vs. denosumab q6mo for postmeno women on ai: denosumab cut fx in half hr 0.50 dfs improved 69% to 74.4% bone mets free survival and od improved bone agents should be considered for pts on adjuvant ai #asco22 
Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine.